Top Buy Now Summary References
Home
>
Section
>
Chapter

Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: a Mini Review

Li, J.; Wang, X.; Li, N.; Jiang, Y.; Huang, H.; Wang, T.; Lin, Z.; Xiong, N.

Current Gene Therapy 20(4): 285-288

2020

ISSN/ISBN: 1875-5631
PMID: 32867652
Accession: 080318503

Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distress syndrome (ARDS) as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients with complications such as cytokine storm syndrome (CSS), who have a high fatality rate. Neither specific anti-SARS-CoV-2 drugs nor vaccines exist currently. Current treatment relies mainly on self-recovery through patients' immune function. Mesenchymal stem cells (MSCs) is a kind of multipotent tissue stem cells, which have powerful anti-inflammatory and immune regulatory functions, inhibiting the cytokine storms. In addition, MSCs have a strong ability to repair tissue damage and reduce the risk of severe complications such as acute lung injury and ARDS, and hopefully, reduce the fatality rate in these patients. There are several clinical types of research completed for treating COVID-19 with MSCs, all reporting restoration of T cells and clinical safety. Here we discuss the clinical prospect and conclude the therapeutic effects and potential mechanism for MSCs in treating COVID-19.

References

Dauletova, M.; Hafsan, H.; Mahhengam, N.; Zekiy, A.O.; Ahmadi, M.; Siahmansouri, H. 2021: Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: a review study Clinical Immunology 226: 108712
Cao, J.-X.; You, J.; Wu, L.-H.; Luo, K.; Wang, Z.-X. 2022: Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: a systematic review World Journal of Clinical Cases 10(27): 9714-9726
Nagoba, B.; Gavkare, A.; Rayate, A.; Mumbre, S. 2022: Positive Aspects, Negative Aspects and Challenges Associated with Stem Cell Therapy for COVID - 19: a Mini-review Current Stem Cell Research and Therapy 17(8): 720-726
Deng, R.; Law, A.H.Y.; Shen, J.; Chan, G.C. 2018: Mini Review: Application of Human Mesenchymal Stem Cells in Gene and Stem Cells Therapy Era Current Stem Cell Reports 4(4): 327-337
Wang, L.-T.; Liu, K.-J.; Sytwu, H.-K.; Yen, M.-L.; Yen, B.L. 2021: Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells Stem Cells Translational Medicine 10(9): 1288-1303
Sengul, F.; Ozturk, B.; Vatansev, H. 2021: Mesenchymal stem cell therapy for COVID-19 American Journal of Stem Cells 10(5): 79-89
Gadkari, R.; Zhao, L.; Teklemariam, T.; Hantash, B.M. 2014: Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy Regenerative Medicine 9(4): 453-465
Kirkham, A.M.; Monaghan, M.; Bailey, A.J.M.; Shorr, R.; Lalu, M.M.; Fergusson, D.A.; Allan, D.S. 2022: Mesenchymal stem/stromal cell-based therapies for COVID-19: first iteration of a living systematic review and meta-analysis: MSCs and COVID-19 CytoTherapy 24(6): 639-649
Rajarshi, K.; Chatterjee, A.; Ray, S. 2020: Combating COVID-19 with mesenchymal stem cell therapy Biotechnology Reports 26: E00467
Alavi-Dana, S.M.M.; Gholami, Y.; Meghdadi, M.; Fadaei, M.S.; Askari, V.R. 2024: Mesenchymal stem cell therapy for COVID-19 infection Inflammopharmacology 32(1): 319-334
Shi, L.; Wang, L.; Xu, R.; Zhang, C.; Xie, Y.; Liu, K.; Li, T.; Hu, W.; Zhen, C.; Wang, F-Sheng. 2021: Mesenchymal stem cell therapy for severe COVID-19 Signal Transduction and Targeted Therapy 6(1): 339
Møller-Hansen, M.; Larsen, A.-C.; Toft, P.B.; Lynggaard, C.D.; Schwartz, C.; Bruunsgaard, H.; Haack-Sørensen, M.; Ekblond, A.; Kastrup, J.; Heegaard, S. 2021: Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease Ocular Surface 19: 43-52
Golchin, A.; Seyedjafari, E.; Ardeshirylajimi, A. 2020: Mesenchymal Stem Cell Therapy for COVID-19: Present or Future Stem Cell Reviews and Reports 16(3): 427-433
Li, C.; Zhao, H.; Wang, B. 2020: Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19 Drug Design Development and Therapy 14: 3995-4001
Häberle, H.; Magunia, H.; Lang, P.; Gloeckner, H.; Körner, A.; Koeppen, M.; Backchoul, T.; Malek, N.; Handgretinger, R.; Rosenberger, P.; Mirakaj, V. 2021: Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS Journal of Intensive Care Medicine 36(6): 681-688
Bamba, C.; Singh, S.P.; Choudhury, S. 2020: Can mesenchymal stem cell therapy be the interim management of COVID-19? Drug Discoveries and Therapeutics 14(3): 139-142
Cao, Y.; Wu, H.; Zhai, W.; Wang, Y.; Li, M.; Li, M.; Yang, L.; Tian, Y.; Song, Y.; Li, J.; Wang, Y.; Ding, Q.; Zhang, L.; Cai, M.; Chang, Z. 2020: A safety consideration of mesenchymal stem cell therapy on COVID-19 Stem Cell Research 49: 102066
Rawat, M.; Ng, C.; Khan, E.; Shah, R.A.; Ashfaq, S.; Bahader, G.A.; Shah, Z.A. 2023: Use of mesenchymal stem cell therapy in COVID-19 related strokes Neural Regeneration Research 18(9): 1881-1883
Xue, J.; Liu, Y. 2023: Mesenchymal Stromal/Stem Cell (MSC)-Based Vector Biomaterials for Clinical Tissue Engineering and Inflammation Research: a Narrative Mini Review Journal of Inflammation Research 16: 257-267
Karakaş, N.; Üçüncüoğlu, S.ül.; Uludağ, D.; Karaoğlan, B.S.; Shah, K.; Öztürk, G.ür. 2022: Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives Cells 11(3)